Business Context and Reporting Period
Company: Radiopharm Theranostics Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: November 4, 2025
Reporting Period: Month of November 2025
Context: The filing serves to disseminate a Public Notice issued to the Australian Securities Exchange regarding a "Notice of Extraordinary General Meeting and Proxy Form."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice regarding a corporate meeting and does not contain financial statements or performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document focuses solely on the administrative scheduling of an Extraordinary General Meeting.
Guidance, Outlook, and Risks
Management Commentary: The Company published a notice to shareholders regarding an upcoming Extraordinary General Meeting. A copy of the notice and proxy form is attached as Exhibit 99.1.
Risks and Contingencies: The filing includes a standard disclaimer stating that the report and its exhibits shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings unless expressly stated.
Unusual Items: None reported.
Investor Verification Checklist
- Verify the specific agenda items and resolutions to be voted on at the Extraordinary General Meeting by reviewing Exhibit 99.1.
- Confirm the record date and deadline for proxy submissions as detailed in the attached Public Notice.
- Note that this filing contains no financial performance data; investors should refer to the most recent Form 20-F or quarterly reports for financial metrics.